Timothy A Yap,Elisa Fontana,Elizabeth K Lee,David R Spigel,Martin Højgaard,Stephanie Lheureux,Niharika B Mettu,Benedito A Carneiro,Louise Carter,Ruth Plummer,Gregory M Cote,Funda Meric-Bernstam,Joseph O'Connell,Joseph D Schonhoft,Marisa Wainszelbaum,Adrian J Fretland,Peter Manley,Yi Xu,Danielle Ulanet,Victoria Rimkunas,Mike Zinda,Maria Koehler,Ian M Silverman,Jorge S Reis-Filho,Ezra Rosen

Abstract:Predictive biomarkers of response are essential to effectively guide targeted cancer treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown to be synthetic lethal with loss of function (LOF) of ataxia telangiectasia-mutated (ATM) kinase, and preclinical studies have identified ATRi-sensitizing alterations in other DNA damage response (DDR) genes. Here we report the results from module 1 of an ongoing phase 1 trial of the ATRi camonsertib (RP-3500) in 120 patients with advanced solid tumors harboring LOF alterations in DDR genes, predicted by chemogenomic CRISPR screens to sensitize tumors to ATRi. Primary objectives were to determine safety and propose a recommended phase 2 dose (RP2D). Secondary objectives were to assess preliminary anti-tumor activity, to characterize camonsertib pharmacokinetics and relationship with pharmacodynamic biomarkers and to evaluate methods for detecting ATRi-sensitizing biomarkers. Camonsertib was well tolerated; anemia was the most common drug-related toxicity (32% grade 3). Preliminary RP2D was 160 mg weekly on days 1-3. Overall clinical response, clinical benefit and molecular response rates across tumor and molecular subtypes in patients who received biologically effective doses of camonsertib (>100 mg d-1) were 13% (13/99), 43% (43/99) and 43% (27/63), respectively. Clinical benefit was highest in ovarian cancer, in tumors with biallelic LOF alterations and in patients with molecular responses. ClinicalTrials.gov registration: NCT04497116 .

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results